As filed with the Securities and Exchange Commission on October 9, 2019 | Registration No. 333 – 234063 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________
pre-effective amendment no. 1 to FORM F-6
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES evidenced by
American depositary receipts
__________________
innate pharma s.a.
(Exact name of issuer of deposited securities as specified in its charter)
__________________
n/a
(Translation of issuer’s name into English)
__________________
france
(Jurisdiction of incorporation or organization of issuer)
_________________________________
CITIBANK, N.A.
(Exact name of depositary as specified in its charter)
__________________
388 Greenwich Street
New York, New York 10013
(877) 248-4237
(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)
__________________
Corporation Service Company
1180 Avenue of the Americas, Suite 210
New York, NY 10036-8401
(800) 927-9801
(Address, including zip code, and telephone number, including area code, of agent for service)
_________________________________
Copies to:
Richard Segal Yvan-Claude Pierre Divakar Gupta Brandon Fenn Cooley LLP 500 Boylston Street, 14th Floor Boston, Massachusetts 02116 (617) 937-2300 | Herman H. Raspé, Esq. Patterson Belknap Webb & Tyler LLP United States of America |
_________________________________
| It is proposed that this filing become effective under Rule 466: | ☐ | immediately upon filing. | |
| ☐ | on (Date) at (Time). |
If a separate registration statement has been filed to register the deposited shares, check the following box: ☒
_________________________________
CALCULATION OF REGISTRATION FEE
| Title of Each Class of Securities to be Registered | Amount to be Registered | Proposed Maximum Aggregate Price Per Unit* | Proposed Maximum Aggregate Offering Price** | Amount of Registration Fee |
| American Depositary Shares (“ADS(s)”), each ADS representing one (1) ordinary share of Innate Pharma S.A. | N/A | N/A | N/A | N/A |
* Each unit represents 100 ADSs. ** Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs. | ||||
The Registrant hereby amends this Registration Statement on Form F-6 on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement on Form F-6 shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Registration Statement on Form F-6 shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
This Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.
ii
PART I
INFORMATION REQUIRED IN PROSPECTUS
Cross Reference Sheet
| Item 1. | DESCRIPTION OF SECURITIES TO BE REGISTERED |
Item Number and Caption | Location in Form of American Depositary Receipt (“Receipt”) | |||
| 1. | Name of Depositary and address of its principal executive office | Face of Receipt – Introductory Article. | ||
| 2. | Title of Receipts and identity of deposited securities | Face of Receipt – Top Center. | ||
| Terms of Deposit: | ||||
| (i) | The amount of deposited securities represented by one American Depositary Share (“ADSs”) | Face of Receipt – Upper right corner. | ||
| (ii) | The procedure for voting, if any, the deposited securities | Reverse of Receipt – Paragraphs (17) and (18). | ||
| (iii) | The collection and distribution of dividends | Reverse of Receipt – Paragraph (15). | ||
| (iv) | The transmission of notices, reports, and proxy soliciting material | Face of Receipt – Paragraph (14); Reverse of Receipt – Paragraph (18). | ||
| (v) | The sale or exercise of rights | Reverse of Receipt – Paragraphs (15) and (17). | ||
| (vi) | The deposit or sale of securities resulting from dividends, splits, or plans of reorganization | Face of Receipt – Paragraphs (3) and (6); Reverse of Receipt – Paragraphs (15) and (17). | ||
| (vii) | Amendment, extension or termination of the deposit agreement | Reverse of Receipt – Paragraphs (23) and (24) (no provision for extensions). | ||
| (viii) | Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs | Face of Receipt – Paragraph (14). | ||
| (ix) | Restrictions upon the right to deposit or withdraw the underlying securities | Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9), and (10). | ||
I-1
Item Number and Caption | Location in Form of American Depositary Receipt (“Receipt”) | |||
| (x) | Limitation upon the liability of the Depositary | Face of Receipt – Paragraph (8); Reverse of Receipt – Paragraphs (20) and (21). | ||
| 3. | Fees and charges which may be imposed directly or indirectly on holders of ADSs | Face of Receipt – Paragraph (11). | ||
| Item 2. | AVAILABLE INFORMATION | Face of Receipt – Paragraph (14). | ||
Innate Pharma S.A. is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s website (www.sec.gov), and can be inspected by holders of ADSs and copied at public reference facilities maintained by the Commission located at 100 F Street, N.E., Washington D.C. 20549, and at the principal executive office of the Depositary.
I-2
PROSPECTUS
The Prospectus consists of the proposed form of American Depositary Receipt attached as Exhibit A to the Form of Deposit Agreement filed as Exhibit (a) to this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 and is incorporated herein by reference.
I-3
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
| Item 3. | EXHIBITS |
| (a) | Form of Deposit Agreement, by and among Innate Pharma S.A. (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. – Filed herewith as Exhibit (a). |
| (b) | Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ___ None. |
| (c) | Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None. |
| (d) | Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Previously filed as exhibit (d) to Registration Statement on Form F-6, Reg. No. 333-234063, filed on October 3, 2019, and incorporated herein by reference. |
| (e) | Certificate under Rule 466. ___ None. |
| (f) | Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages to Registration Statement on Form F-6, Reg. No. 333-234063, filed on October 3, 2019, and incorporated herein by reference. |
II-1
| Item 4. | UNDERTAKINGS |
| (a) | The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer. |
| (b) | If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule. |
II-2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement by and among Innate Pharma S.A., Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 9th day of October, 2019.
Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive one (1) ordinary share of Innate Pharma S.A. | ||
CITIBANK, N.A., solely in its capacity as Depositary | ||
| By: | /s/ Keith Galfo | |
| Name: Keith Galfo | ||
| Title: Vice President | ||
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Innate Pharma S.A. certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Marseille, France, on October 9, 2019.
| INNATE PHARMA S.A. | ||
| By: | /s/ Mondher Mahjoubi | |
| Name: Mondher Mahjoubi | ||
| Title: Chief Executive Officer | ||
II-4
Pursuant to the requirements of the Securities Act of 1933, as amended, this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
/s/ Mondher Mahjoubi | Chief Executive Officer and | October 9, 2019 | ||
Name: Mondher Mahjoubi (Principal Executive Officer) | Chairman of the Executive Board | |||
/s/ Laure-Hélène Mercier | Chief Financial Officer and | October 9, 2019 | ||
| Name: Laure-Hélène Mercier (Principal Financial Officer / Principal Accounting Officer) | Member of the Executive Board | |||
| * | Chairman of the Supervisory Board | October 9, 2019 | ||
| Name: Hervé Brailly | ||||
| * | Vice-Chairman of the Supervisory Board | October 9, 2019 | ||
| Name: Irina Staatz-Granzer | ||||
| * | Member of the Supervisory Board | October 9, 2019 | ||
| Name: Jean-Yves Blay | ||||
| * | Member of the Supervisory Board | October 9, 2019 | ||
| Name: Gilles Brisson | ||||
| * | Member of the Supervisory Board | October 9, 2019 | ||
| Name: Véronique Chabernaud | ||||
| * | Member of the Supervisory Board | October 9, 2019 | ||
Bpifrance Participations, represented by Maïlys Ferrere | ||||
| * | Member of the Supervisory Board | October 9, 2019 | ||
| Name: Patrick Langlois |
| Signature | Title | Date | |||
| * | |||||
Novo Nordisk A/S, represented by Marcus Schindler | Member of the Supervisory Board | October 9, 2019 | |||
| /s/ Mondher Mahjoubi | Authorized Representative in the United States | October 9, 2019 | |||
Innate Pharma, Inc. By: Mondher Mahjoubi, President | |||||
| By: | /s/ Mondher Mahjoubi | ||||
Mondher Mahjoubi Attorney-in-fact | |||||
Index to Exhibits
| Exhibit | Document | Sequentially Numbered Page |
| (a) | Form of Deposit Agreement |